Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_assertion type Assertion NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_head.
- NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_assertion description "[Patients who had progressed during or after first-line chemotherapy were prospectively assigned to EGFR-TKI treatment as follows: (G1) EGFR mutation (n = 12); (G2) highly polysomic/amplified EGFR (n = 18); (G3) EGFR and/or pAKT positive (n = 41); (G4) adenocarcinoma/bronchoalveolar carcinoma and no smoking history (n = 15).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_provenance.
- NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_assertion evidence source_evidence_literature NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_provenance.
- NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_assertion SIO_000772 22425916 NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_provenance.
- NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_assertion wasDerivedFrom befree-20140225 NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_provenance.
- NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_assertion wasGeneratedBy ECO_0000203 NP209505.RADEclJiJUH7Pj6Wigv1RlqqHna3wbIUdKg33xtpJ9340130_provenance.